Natriuretic Peptides
7 compounds in this family, each with its recorded mechanism, routes of administration, safety notes and references to published literature.
- .gamma.-brain natriuretic peptideγ‑Brain natriuretic peptide (γ‑BNP) is the high‑molecular‑weight, 106‑amino‑acid precursor of the cardiac hormone brain natriuretic peptide. It contains the C‑terminal BNP‑32 sequence and is stored in cardiac atrium and other tissues such as the adrenal gland. In normal plasma the γ‑form is the predominant circulating species, whereas BNP‑32 dominates in heart tissue. Plasma γ‑BNP rises markedly in heart disease and experimental hypertension, indicating its role as a marker of cardiac BNP synthesis and storage.
- AnaritideAnaritide is a synthetic 25‑amino‑acid analogue of atrial natriuretic peptide (ANP) belonging to the natriuretic peptide family. It has been studied as a potential therapy for conditions involving fluid overload and renal dysfunction, such as acute tubular necrosis, oliguric acute renal failure, cirrhosis‑related ascites, and radiocontrast‑induced nephropathy. While some reviews cite regulatory approval for acute decompensated heart failure, the compound is generally listed as investigational.
- Atrial natriuretic peptideAtrial natriuretic peptide (ANP) is a cardiac hormone belonging to the natriuretic peptide family. It is investigated primarily for its ability to protect kidney function during acute illness and to influence metabolic pathways such as lipolysis. Research has focused on low‑dose intravenous or subcutaneous administration to prevent or treat acute kidney injury (AKI) and to explore effects on blood pressure and adipokine regulation.
- CenderitideCenderitide (CD‑NP) is a designer natriuretic peptide engineered by fusing C‑type natriuretic peptide to the C‑terminus of dendroaspis natriuretic peptide. It is being investigated as an intravenous or subcutaneous therapy for heart failure and related cardiorenal disorders, aiming to enhance renal function and limit cardiac fibrosis while avoiding marked blood‑pressure drops.
- NesiritideNesiritide (Natrecor) is a recombinant form of human BNP approved for the intravenous treatment of acutely decompensated congestive heart failure with dyspnea at rest or minimal activity. It produces balanced arterial and venous vasodilation and promotes diuresis and natriuresis.
- UlaritideUlaritide is a synthetic analogue of the kidney‑derived natriuretic peptide urodilatin. It is being investigated as an intravenous therapy for acute decompensated heart failure (ADHF) and related circulatory disorders. The peptide is intended to promote vasodilation, natriuresis and diuresis, thereby lowering cardiac filling pressures and improving symptoms of dyspnoea.
- VosoritideVosoritide is a synthetic analogue of the C‑type natriuretic peptide (CNP) that has been approved as a prescription therapy for children with achondroplasia, the most common genetic skeletal dysplasia. By targeting the molecular defect that impairs endochondral ossification, it aims to increase linear growth and improve body proportions in affected pediatric patients.